Fochon Biosciences

Fochon Biosciences is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics, primarily in the fields of oncology and metabolic diseases. As a key R&D subsidiary of Fosun Pharma, the company leverages its robust research platforms in Chongqing and Shanghai to advance a diverse pipeline of targeted therapies. Its lead programs include highly selective inhibitors for MEK, CDK4/6, and ALK/ROS1, with several candidates currently in late-stage clinical trials. Fochon has successfully established significant global partnerships, including licensing agreements with major pharmaceutical companies to co-develop its proprietary assets for international markets.